XORTX Therapeutics Inc (XRTX) — Cash Flow-to-Debt Ratio
XORTX Therapeutics Inc (XRTX) has a Cash Flow-to-Debt Ratio of -0.75x as of September 2025, meaning its operating cash flow of CA$-629.62K could theoretically repay -1% of its total liabilities (CA$837.41K) in one year. See XORTX Therapeutics Inc free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
XORTX Therapeutics Inc Cash Flow-to-Debt Ratio (2018–2024)
Historical debt coverage capacity for XORTX Therapeutics Inc across 7 annual periods. Also explore XRTX net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for XORTX Therapeutics Inc (2018–2024)
Year-by-year debt coverage analysis for XORTX Therapeutics Inc. For market capitalisation and broader financial context, see XORTX Therapeutics Inc market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (CAD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -4.85x | CA$-3.68 Million | CA$757.99K | ▲ +39.1% |
| 2023 | -7.97x | CA$-6.58 Million | CA$825.94K | ▼ -257.5% |
| 2022 | -2.23x | CA$-11.97 Million | CA$5.37 Million | ▼ -94.8% |
| 2021 | -1.14x | CA$-6.06 Million | CA$5.30 Million | ▼ -62.5% |
| 2020 | -0.70x | CA$-728.40K | CA$1.03 Million | ▼ -266.8% |
| 2019 | -0.19x | CA$-249.58K | CA$1.30 Million | ▲ +88.3% |
| 2018 | -1.65x | CA$-1.56 Million | CA$943.70K | — |